Ajanta Pharma reports 14% revenue growth in Q1

Ajanta Pharma reported 14% revenue growth to ₹1,303 cr in Q1 FY26, up from ₹1,145 cr the previous year. EBITDA rose 6% to ₹351 cr and profit after tax increased 4% to ₹255 cr.

Excluding a ₹25 cr mark-to-market forex loss, EBITDA grew 14% with a 29% margin, while PAT grew 12% with a 21% margin.

Branded generics, representing 73% of total revenue, increased 9% to ₹941 cr. India's branded generics revenue jumped 16% to ₹409 cr, while Asia grew 10% to ₹304 cr.

US generics revenue surged 36% to ₹310 cr, reflecting the company's "selective play" approach. The company has 47 products on shelf and 21 pending approvals in the US market.